The content on this site is intended for healthcare professionals only
Dr Michael Bishop speaks to ecancer about the analysis of the phase III Belinda study.
This study investigates tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma.
Initially, he talks about the background of the study. Dr Bishop then discusses the methods and results of this study.
He says that tisa-cel as 2nd line treatment in R/R aNHL patients did not have a higher event-free survival vs standard of care.
He concludes by saying that results from this randomised phase III study will inform use of cellular treatment in the 2L R/R aNHL setting and the design of future CAR-T trials.
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia
Ide-cell enhances health-related quality of life for refractory multiple myeloma
BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL
